Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

ProTrans

Phase 1Biologic

NNextCell Pharma Ab

1

Indications

2

Total Trials

1

Active Trials

0

Competitors

Timeline

Expected Milestones

Q2 2027

Phase 1Active, not recruiting

Complication

NCT04896853

Clinical

Trials by Indication[1]

Treatment1 trial

Wharton´s Jelly Derived Mesenchymal Stromal Cell Repeated Treatment of Adult Patients Diagnosed with Type I Diabetes

Completed·NNextCell Pharma Ab·Phase 1/2·NCT03973827·15 enrolled

Complication1 trial

Treatment of Respiratory Complications Associated With COVID19,Influenza ,Metapneumovirus,RSV Infection Using ProTrans®

Active, not recruiting·NNextCell Pharma Ab·Phase 1·NCT04896853·9 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for ProTrans. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ProTrans compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ProTrans. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — NextCell Pharma Ab company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: NNextCell Pharma Ab

Related News